Prostatic endoprosthesis in the treatment of prostatic obstruction: preliminary experience with the new Trestle model
Cecchi, M.; Sepich, C.A.; Pagni, G.L.; Summonti, D.; Ippolito, C.; Di Benedetto, A.; Bertolini, L.; Minervini, R.; Fiorentini, L.
Chirurgia Italiana 50(1): 37-40
1998
ISSN/ISBN: 0009-4773 PMID: 9732822 Document Number: 488495
The urethral stent is a relatively new treatment modality for benign prostatic hypertrophy ostruction. Although the ultimate prostatic endoprosthesis has yet to be developed, various stents have been produced and investigated with good results. We review the several currently available stents and we report the preliminary clinical experience with a new device (Trestle).
Document emailed within 1 workday
Related Documents
Bordes, M.; Brunet-Lecomte, P.; Dusserre, P.; Dusserre-Guion, L.; Michiels-Marzais, D.; Morlevat, F.; Peny, J.; Roignot, P.; Colas, J.M.; Ferry, N. 1989: Prostatic specific antigen and prostatic pathology. Value of preoperative blood assay. Preliminary study apropos of 709 case reports Annales d'Urologie 23(4): 295-300Lowe, F.C.; Isaacs, J.T. 1984: Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a model Cancer Research 44(2): 744-752
Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Leńko, J.; Marczyńska, A.; Kulpa, J.; Kwinta, A.; Bugajski, A. 1986: Biochemical control investigations (determinations of prostatic phosphatase--carcinoembryonic antigen alkaline phosphatase) in patients treated for prostatic carcinoma. Preliminary estimation of effectiveness Materia Medica Polona. Polish Journal of Medicine and Pharmacy 18(4): 238-243
Granados Loarca, E.A. 1999: Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume Archivos Espanoles de Urologia 52(3): 201-208
Steg, A.; Chiche, R.; Boccon-Gibod, L.; Debré, B.; Duchier, J.; Schally, A.V. 1984: Treatment of prostatic cancer with an LH-RH agonist: the D Trp6 LH-RH. Preliminary results in 30 cases Annales d'Urologie 18(6): 388-392
Larosa, M.; Ferretti, S.; Salsi, P.; Simonazzi, M. 1994: Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): our experience Acta Bio-Medica de l'Ateneo Parmense 65(1-2): 23-28
Vieillefond, A.; Berger, N.; Dauge-Geffroy, M.C.; Saint Andre, J.P. 1993: Prostatic adenosis and dysplasia. what is their definition... and their significance? Are there "precancerous" lesions in prostatic pathology? Annales de Pathologie 13(2): 85-87
Bouffioux, C. 1983: Prostatic cytology. Value of the technic in the diagnosis and surveillance of prostatic carcinomas; viewpoint of the urologist Acta Urologica Belgica 51(1): 56-71
Sáenz de Chirife, A.M.; Bassi, A.M.; Celeste, F.; Bergdolt, D. 1991: Specific prostatic antigen in prostatic carcinoma: its relationship with tumor differentiation and clinical course Archivos Espanoles de Urologia 44(4): 405-409
Brannen, G.E.; Coffey, D.S. 1977: Tumor-specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia Cancer Treatment Reports 61(2): 211-216
Svanholm, H.; Hørder, M. 1988: Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques Scandinavian Journal of Urology and Nephrology. Supplementum 107: 65-70
Kupriyanov, Y.A.; Rasner, P.I.; Rokhlikov, I.M.; Akrikidi, A.A.; Soloviev, V.V.; Markov, A.A.; Nozdrin, E.V.; Logvinov, L.A.; Vasilevskiy, R.P.; Skrupskiy, K.S.; Pushkar, D.Y.; Putilovskiy, M.A.; Epstein, O.I. 2019: The experience of using drug Afalaza for treatment of lower urinary symptoms in treatment-nave patients with benign prostatic hyperplasia Urologiia 3: 36-42
Paul, B.D.; Serrano, J.A.; Friedman, A.E.; Sarlos, I.J.; Sternberger, N.J.; Wasserkrug, H.L.; Seligman, A.M. 1977: New agents for prostatic cancer activated specifically by prostatic acid phosphatase Cancer Treatment Reports 61(2): 259-263
Kletscher, B.A.; Oesterling, J.E. 1995: Prostatic stents. Current perspectives for the management of benign prostatic hyperplasia Urologic Clinics of North America 22(2): 423-430
Strohmenger, P. 1980: Prostatic adenoma--prostatic carcinoma. Questions from general practice. II. Therapy Zfa. Zeitschrift für Allgemeinmedizin 56(28): 1793-1797
Rodríguez Rodríguez, R.; Mayayo Dehesa, T.; Galbis Sanjuan, F.; Burgos Revilla, F.J.; Jiménez Cidre, M.; García González, R. 1996: Chronic prostatic inflammation: a confounding factor in the diagnosis of prostatic cancer Archivos Espanoles de Urologia 49(7): 669-673
Gu, F. 2000: Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China Chinese Medical Journal 113(4): 299-302
Kazama, T.; Mizuno, I.; Takamine, T.; Umeda, K.; Terada, T.; Ishikawa, S.; Fuse, H.; Katayama, T. 1990: Evaluation of anti-androgen therapy for benign prostatic hypertrophy by using transrectal prostatic ultrasonography Hinyokika Kiyo. Acta Urologica Japonica 36(12): 1423-1427
Blanc, M.; Sacrini, A.; Avogadro, A.; Gattamorta, M.; Lazzerini, F.; Gattoni, F.; Cretti, F. 1998: Prostatic volume: suprapubic versus transrectal ultrasonography in the control of benign prostatic hyperplasia La Radiologia Medica 95(3): 182-187